Kirsty's Mounjaro restart video raises questions about pausing
Quick answer
The creator stopped tirzepatide five weeks prior and regained approximately 4.1kg from her lowest recorded weight, consistent with expected post-cessation rebound documented in the SURMOUNT-4 trial. She is restarting at 0.5mg rather than the approved 2.5mg starting dose, which deviates from TGA and FDA prescribing guidelines and increases gastrointestinal side effect risk without evidence of benefit. She self-reports the deviation and advises viewers to follow the correct titration schedule, which partially mitigates the harm potential of her own example.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @keepingwithkirsty actually say?
Kirsty is five weeks off tirzepatide (Mounjaro) and restarting today at 0.5mg, skipping the standard 2.5mg starting dose. She weighs 79.6kg, up from a low of 75.5kg during her previous run. She explicitly says "I do not recommend this" about jumping straight to 0.5mg, and tells viewers to start at 2.5mg and work up if they're restarting. She also talks about wanting to reduce what she calls "inflammation" in her body, and plans to get back into gym training alongside the medication.
To be clear about the dosing: standard tirzepatide titration begins at 2.5mg weekly for four weeks before stepping up. Kirsty is doubling that starting dose on her own initiative. She's aware it's off-label behaviour and flags it. That self-awareness matters, but it doesn't neutralise the risk for viewers who might copy her without the same context.
Does the science back this up?
The rebound weight after stopping GLP-1 medications is well-documented and real. Her 4.1kg regain over five weeks is consistent with published data. The "inflammation" framing, though, is doing a lot of work here and deserves scrutiny.
The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed that participants who stopped tirzepatide after 36 weeks regained roughly two-thirds of their lost weight within a year. Five weeks of regain is a normal physiological response, not a sign of personal failure. The body defends its prior weight set point through hormonal and metabolic mechanisms, particularly through ghrelin and leptin signalling, and tirzepatide's dual GIP/GLP-1 agonism suppresses appetite in ways that reverse quickly after cessation.
On the inflammation claim: there is emerging evidence that tirzepatide reduces markers of systemic inflammation, including C-reactive protein and interleukin-6 (Frias et al., 2021, New England Journal of Medicine). But attributing belly bloating primarily to "inflammation" is imprecise. Visceral fat redistribution, gut motility changes after stopping the drug, and simple caloric rebound all contribute. Kirsty isn't wrong that something is happening, she's just using a loosely defined term for a complex set of changes.
What did they get wrong (or right)?
The titration advice she gives viewers is actually correct. Starting at 2.5mg and working up is the approved protocol, and she says so plainly. Credit where it's due. Her transparency about ignoring her own advice is unusual in this content space, where most creators present their choices as templates.
Where things get shaky: jumping to 0.5mg on restart. Tirzepatide's approved dosing schedule (TGA and FDA alike) starts at 2.5mg for a reason. The gastrointestinal side effects, nausea, vomiting, and delayed gastric emptying, are dose-dependent. Starting higher increases the likelihood of significant GI distress. There's no published evidence that resuming at a higher starting dose produces faster or better outcomes. A 2023 review by Nauck and D'Alessio in Nature Reviews Endocrinology notes that tolerability-driven titration is central to GLP-1 class safety, and skipping steps is explicitly discouraged in prescribing guidelines.
Her weight regain numbers are plausible and her self-monitoring is reasonable. She is not making any disease cure claims, which keeps her within safer territory than many GLP-1 creators on the platform.
What should you actually know?
If you're considering stopping and restarting tirzepatide, the evidence is clear: weight regain after stopping is expected, not exceptional. The SURMOUNT-4 data suggest that continuous treatment outperforms stop-start cycling for sustained weight loss, though cycling may be a practical reality for people managing cost or supply issues.
On restart dosing, the prescribing information is not ambiguous. You restart at 2.5mg. Your prescriber may adjust this based on your history and how long you were off the drug, but that is a clinical decision, not a personal one based on impatience. Starting too high does not speed up results. It increases the chance you'll spend the first two weeks feeling sick enough to quit again.
The "inflammation" narrative circulating in GLP-1 communities online often conflates several distinct things: visceral adiposity, gut microbiome shifts, actual inflammatory markers, and subjective bloating. These are related but not identical. Tirzepatide does appear to have anti-inflammatory effects beyond weight loss alone, but that is a research finding, not a feature you can feel in your belly after five weeks off the drug.
- Weight regain after stopping GLP-1 medications is a pharmacological expectation, not a willpower failure.
- Restart dosing should follow clinical guidance, starting at 2.5mg, not personal preference.
- The "inflammation" framing is imprecise. Some of what Kirsty describes is likely fluid shifts and visceral fat redistribution, not systemic inflammation.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Kirsty's Mounjaro restart video raises questions about pausing, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Claim verdict
The useful answer behind this video
Claim being checked
The creator stopped tirzepatide five weeks prior and regained approximately 4.
FormBlends verdict
The creator stopped tirzepatide five weeks prior and regained approximately 4.1kg from her lowest recorded weight, consistent with expected post-cessation rebound documented in the SURMOUNT-4 trial. She is restarting at 0.5mg rather than the approved 2.5mg starting dose, which deviates from TGA and FDA prescribing guidelines and increases gastrointestinal side effect risk without evidence of benefit. She self-reports the deviation and advises viewers to follow the correct titration schedule, which partially mitigates the harm potential of her own example.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator stopped tirzepatide five weeks prior and regained approximately 4.1kg from her lowest recorded weight, consistent with expected post-cessation rebound documented in the SURMOUNT-4 trial. She is restarting at 0.5mg rather than the approved 2.5mg starting dose, which deviates from TGA and FDA prescribing guidelines and increases gastrointestinal side effect risk without evidence of benefit. She self-reports the deviation and advises viewers to follow the correct titration schedule, which partially mitigates the harm potential of her own example.
- SURMOUNT-4 (Aronne et al., 2024, JAMA): participants regained roughly two-thirds of lost weight within 12 months of stopping tirzepatide, making Kirsty's 4.1kg regain in five weeks a predictable pharmacological outcome, not a personal failure.
- TGA and FDA prescribing guidelines for tirzepatide specify a 2.5mg restart dose regardless of prior treatment history. Starting at 0.5mg doubles the approved starting dose and increases gastrointestinal side effect risk without evidence of faster results.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- SURMOUNT-4 (Aronne et al., 2024, JAMA): participants regained roughly two-thirds of lost weight within 12 months of stopping tirzepatide, making Kirsty's 4.1kg regain in five weeks a predictable pharmacological outcome, not a personal failure.
- TGA and FDA prescribing guidelines for tirzepatide specify a 2.5mg restart dose regardless of prior treatment history. Starting at 0.5mg doubles the approved starting dose and increases gastrointestinal side effect risk without evidence of faster results.
- Tirzepatide does have measurable anti-inflammatory effects beyond weight loss, including reductions in CRP and IL-6 (Frias et al., 2021, NEJM), but 'inflammation' as used in this video is an imprecise term that blends several distinct physiological processes.
- Continuous tirzepatide use outperforms stop-start cycling for sustained weight loss based on SURMOUNT-4 data. If cycling is necessary due to cost or supply, the restart protocol should still follow clinical titration schedules.
- Kirsty correctly tells viewers to start at 2.5mg if restarting, then ignores her own advice. Viewers should follow the guideline she gives, not the example she sets.
- Weight fluctuations of 1-2kg around a low recorded weight are consistent with normal fluid shifts and do not represent meaningful fat mass changes, a point worth noting when interpreting personal weight tracking data from any creator.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Kirsty 🤎✨ · TikTok creator
29.3K views on this video
Week 34 (5 weeks post MJ) RESTARTING DAY ✨🙌 #mounjaro #mounjarojourney #mounjaroaustralia
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Kirsty 🤎✨, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.